Prof. Dr. Martin Storr
Prof. Dr. Martin Storr
Verified email at med.uni-muenchen.de
Title
Cited by
Cited by
Year
The endogenous cannabinoid system protects against colonic inflammation
F Massa, G Marsicano, H Hermann, A Cannich, K Monory, BF Cravatt, ...
The Journal of clinical investigation 113 (8), 1202-1209, 2004
4632004
Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults
AJ Lucendo, J Molina-Infante, Á Arias, U von Arnim, AJ Bredenoord, ...
United European gastroenterology journal 5 (3), 335-358, 2017
3802017
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, HJ Woerle, ...
Gut 55 (2), 243-251, 2006
2792006
Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by 1H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and …
R Schicho, R Shaykhutdinov, J Ngo, A Nazyrova, C Schneider, ...
Journal of proteome research 11 (6), 3344-3357, 2012
1852012
Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up
HD Allescher, M Storr, M Seige, R Gonzales-Donoso, R Ott, P Born, ...
Endoscopy 33 (12), 1007-1017, 2001
1712001
The endocannabinoid system controls food intake via olfactory processes
E Soria-Gómez, L Bellocchio, L Reguero, G Lepousez, C Martin, ...
Nature neuroscience 17 (3), 407-415, 2014
1702014
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis
MA Storr, CM Keenan, H Zhang, KD Patel, A Makriyannis, KA Sharkey
Inflammatory bowel diseases 15 (11), 1678-1685, 2009
1642009
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors
MA Storr, CM Keenan, D Emmerdinger, H Zhang, B Yüce, A Sibaev, ...
Journal of molecular medicine 86 (8), 925-936, 2008
1602008
Distribution, function and physiological role of melatonin in the lower gut
CQ Chen, J Fichna, M Bashashati, YY Li, M Storr
World journal of gastroenterology: WJG 17 (34), 3888, 2011
1552011
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
F Massa, M Storr, B Lutz
Journal of molecular medicine 83 (12), 944-954, 2005
1482005
Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity
S Klein, B Seidler, A Kettenberger, A Sibaev, M Rohn, R Feil, ...
Nature communications 4 (1), 1-9, 2013
1462013
Eosinophilic colitis: epidemiology, clinical features, and current management
AA Alfadda, MA Storr, EA Shaffer
Therapeutic advances in gastroenterology 4 (5), 301-309, 2011
1412011
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives
M Sobczak, M Sałaga, MA Storr, J Fichna
Journal of gastroenterology 49 (1), 24-45, 2014
1232014
Brain-gut interactions in IBS
J Fichna, M Storr
Frontiers in Pharmacology 3, 127, 2012
1202012
The pathophysiology of chronic constipation
CN Andrews, M Storr
Canadian Journal of Gastroenterology 25, 2011
1162011
Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up
M Storr, HD Allescher, T Rösch, P Born, N Weigert, M Classen
Gastrointestinal endoscopy 54 (6), 754-759, 2001
1162001
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro
S Brand, J Dambacher, F Beigel, K Zitzmann, MHJ Heeg, TS Weiss, ...
American Journal of Physiology-Gastrointestinal and Liver Physiology 292 (4 …, 2007
1152007
Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease
M Storr, S Devlin, GG Kaplan, R Panaccione, CN Andrews
Inflammatory bowel diseases 20 (3), 472-480, 2014
1122014
The endocannabinoid system and gut–brain signalling
MA Storr, KA Sharkey
Current opinion in pharmacology 7 (6), 575-582, 2007
1112007
STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders
B Ottillinger, M Storr, P Malfertheiner, HD Allescher
Wiener Medizinische Wochenschrift 163 (3-4), 65-72, 2013
1102013
The system can't perform the operation now. Try again later.
Articles 1–20